CompletedPhase 1/2

ODM-207 in Patients With Advance Solid Tumours

Finland36 participantsStarted 2016-12-22

Plain-language summary

This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic cancer for which no effective standard therapy exists or are refractory or resistant to conventional therapy * Life expectancy \>12 weeks * Patient may have either measurable or non-measurable disease, but must have disease that can be evaluated for improvement of progression * ECOG performance status of 0 to 1 Exclusion Criteria: * History of bleeding disorder or significant bleeding episode within 6 months prior to study treatment * Subjects receiving anticoagulants or medications that durably inhibit platelet function (7-day wash-out prior to study treatment) * History of or current leptomeningeal or brain metastasis or spinal cord compression.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Maximum Tolerated Dose

Timeframe: 28 days

Trial details

NCT IDNCT03035591

SponsorOrion Corporation, Orion Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-05-10

View on ClinicalTrials.gov More Solid Tumors trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.